Advm股票zacks
ADVM: Adverum Biotechnologies Inc Detailed Estimate. Get the latest Detailed Estimate from Zacks Investment Research. ADVM: Adverum Biotechnologies Inc - Interactive Chart Chart. Get the latest Interactive Chart for Adverum Biotechnologies Inc from Zacks Investment Research Zacks' proprietary data indicates that Adverum Biotechnologies, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the ADVM shares relative to the market in the ADVM Adverum Biotechnologies traded up $0.58 at close of the trading on Wednesday, hitting $21.14 daily high and touching the bottom line at 18.82. The company had a trading volume of 802796 shares, compared to its average volume of 1460270. The company has a BETA of 2.11. ADVM Adverum Biotechnologies has a 12-month low of $4.96 and a 12-month high of $23.79. Zacks Investment Research upgraded shares of Adverum Biotechnologies (NASDAQ:ADVM) from a hold rating to a buy rating in a research note issued to investors on Monday, Zacks.com reports. They currently have $23.00 price objective on the biotechnology company’s stock. According to Zacks, “Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular […] Zacks Investment Research upgraded shares of Adverum Biotechnologies (NASDAQ:ADVM) from a hold rating to a buy rating in a research report released on Monday morning, Zacks.com reports. The firm currently has $13.00 target price on the biotechnology company’s stock. According to Zacks, “Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular […] Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Apr. 28, 2020 at 12:00 p.m. ET on
问：没有股票经验，只想买指数做长期投资，如何判断买卖点？ 现在可以进吗？ 这个问题最常见，答案也有很多，今天介绍一个最简单的方法，即以对比指数 10年期回报和P/E ratio的关系。
Zacks Investment Research downgraded shares of Adverum Biotechnologies (NASDAQ:ADVM) from a buy rating to a hold rating in a research report released on Wednesday, Zacks.com reports. According to Zacks, “Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable […] Zacks Investment Research lowered shares of Adverum Biotechnologies (NASDAQ:ADVM) from a buy rating to a hold rating in a report issued on Tuesday morning, Zacks.com reports. According to Zacks, “Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable […] Adverum Biotechnologies (ADVM) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.23 per share a year ago. These
Immunomedics (IMMU) reports a narrower-than-expected Q1 loss. The focus is on its recently approved drug, Trodelvy, for mTNBC. May. 7, 2020 at 11:21 a.m. ET on Zacks.com
Ever Trading: 2018
股吧个股吧列表_东方财富网旗下股票社区_东方财富网股吧
(pme)平潭海洋实业 (ptr)中石油 (rcon)研控科技 (renn)人人网 (seed)奥瑞金种业 (sfun)房天下控股 (sgoc)上为集团 (shi)上海石化 (simo)慧荣科技 (sina JD.com, Inc. American Depositary Shares (JD) Stock Quotes ... JD.com, Inc. American Depositary Shares (JD) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
新浪财经-美股频道为您提供advm(advm)股票股价,股票实时行情,新闻,财报,美股实时交易数据,研究报告,评级,财务指标分析等与advm(advm)股票相关的信息与服务
Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Apr. 28, 2020 at 12:00 p.m. ET on Adverum Biotechnologies (NASDAQ:ADVM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to […] ADVM is currently sporting a Zacks Rank of #2 (Buy). Within the past quarter, the Zacks Consensus Estimate for ADVM's full-year earnings has moved 4.62% higher. This signals that analyst sentiment Zacks Investment Research downgraded shares of Adverum Biotechnologies (NASDAQ:ADVM) from a buy rating to a hold rating in a research report released on Wednesday, Zacks.com reports. According to Zacks, “Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable […] Zacks Investment Research lowered shares of Adverum Biotechnologies (NASDAQ:ADVM) from a buy rating to a hold rating in a report issued on Tuesday morning, Zacks.com reports. According to Zacks, “Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable […] Adverum Biotechnologies (ADVM) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.23 per share a year ago. These